Immunomodulators Market

Immunomodulators Market Size

The global immunomodulators market size was valued at around USD 217.7 billion in 2023 and is estimated to grow at 6.7% CAGR from 2024 to 2032. Immunomodulators are substances that alter one or more immune processes. These agents may increase the immune system activity (immunostimulants) or reduce it (immunosuppressants), which makes them highly valuable in treating various conditions such as autoimmune disorders, cancers, and persistent infections.

The factors driving demand for immunomodulators include the increasing burden of autoimmune and inflammatory diseases, newer developments in biotechnological and pharmaceutical industries, and increased focus on the use of these therapies. In addition, rising expenditures in healthcare and the need for better therapeutics are supporting this expansion. The increase in post-COVID syndrome patients has greatly expanded the immunomodulator market. As highlighted in a recent study, post-COVID-19 respiratory problems have soared the demand for immunotherapies ever more, not least because vaccine rollout is insufficient. These approaches are well-documented to improve a person’s immunity to the virus, and in the coming years will lead to a growth of the market.

The focus on growing the customer base is giving companies a competitive advantage. The major players are strategically undertaking mergers, acquisitions, and joint ventures with other important firms. For instance, Merck & Co., Inc. declared the purchase of Pandion Therapeutics, Inc. in February 2021. Pandion is a clinical-stage biotech company focused on novel therapeutics for autoimmune diseases. Through its TALON technology, Pandion Therapeutics was able to build a strong pipeline of candidates that aimed at immune rebalancing for a broad scope of autoimmune disorders. This purchase allowed Merck to further fuel their strategy of seeking and acquiring candidates with unique and potentially fundamental traits.

Immunomodulators Market Trends

• The increase in acceptance of immunomodulator therapy for treating Crohn’s disease is expected to accelerate market growth. As per a report by MedlinePlus, Western Europe and North America had the highest Crohn’s disease prevalence in 2022, with incidences between 100 and 300 per 100,000 people. Furthermore, over 500,000 citizens in the USA suffered from Crohn’s disease and the need for immunomodulator therapies soared.
  
• In addition, new improvements in immunomodulatory therapy such as CAR-T cell therapy and checkpoint inhibitors not only helped in lowering the organ rejection rates but also made it easier to achieve remission, which is further proof that these treatments are proving to be more advantageous.
  
• Additionally, the growing use of immunomodulator therapy is fueled by the rising global occurrence of multiple sclerosis, which is estimated to affect over 2.9 million people around the world and nearly one million people in the U.S., according to the National Multiple Sclerosis Society.
  

Immunomodulators Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on product type, the market is bifurcated into immunosuppressants and immunostimulants. The immunosuppressants segment dominated the market with the largest revenue of USD 136.5 billion in 2023 and is expected to grow at a significant CAGR over the forecast period.

• The growing world adoption of some organ transplant procedures accelerates the invention of efficient medications against such organ transplant rejections. For instance, Global Observatory on Donation and Transplantation reports that about 153,863 organ transplants were done globally in 2022, marking a continuous rise in organ transplanting procedures.
  
• The increasing involvement of AI is one reason for concern and a level of willingness. Apart from that, the growing number of autoimmune disorders makes the use of immunosuppressive medications more common. The National Institutes of Health (NIH) estimates that autoimmune diseases have an impact on 23.5 million Americans, a good fraction of the population.
  
• Together, these factors drive the high demand for immunosuppressive therapies, addressing vital needs in transplant medicine and the management of autoimmune diseases.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the immunomodulators market is segmented into oncology, autoimmune diseases, infectious diseases, and other applications. The oncology segment dominated the market and was valued at USD 85.4 billion in 2023.

• An increasing number of patients and growing cancer awareness is fueling the oncology market, which results in increasing use of immunomodulatory agents and therapies. These agents, such as immune checkpoint inhibitors, cytokines, and cancer vaccines, aim either to enhance the immune system's primary attack on tumors or create a more favorable immune environment for anti-tumor responses.
  
• Furthermore, the demand for novel immunomodulatory therapies to combat cancer continues to rise. According to the WHO, cancer ranks second among the leading causes of death globally. Nearly 10 million people died due to cancer in 2020. The scope for new therapies for cancer treatment is vast. The large number of fatalities represents significant opportunities for new cancer treatment therapies, which in turn fuels the need for oncology immunomodulators.
  
• This segmentation is expected to exhibit sustained growth during the forecast period. The factors mentioned above are likely to contribute to growth in this segment.
  

Based on distribution channel, the immunomodulators market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest revenue of USD 119.3 billion in 2023.

• The primary reason for the increased revenue share of the hospital pharmacy segment stems from the need to properly handle and store immunomodulator treatments such as biologics or monoclonal antibodies, which typically require specialized administration via injection or infusion. These treatments are usually administered in clinical facilities for safety reasons.
  
• Additionally, medical professionals must carefully manage complications that may arise from these medications. Patients often require intensive care from healthcare providers. Hospital pharmacy segments maintain their dominant share through established healthcare systems and professional expertise.
  

Looking for region specific data?

Download Free PDF

The North America immunomodulators market is forecasted to reach USD 178.3 billion by 2032. The U.S. dominated the North America market with the largest revenue of USD 91.2 billion in 2023.

• The primary reason for the region's dominance is the increase in chronic diseases. The CDC has reported that around 6 out of 10 adults in the U.S. suffer from a chronic disease. Furthermore, 40% of the adult population has two or more chronic conditions. This higher incidence rate has resulted in increased need and use of immunomodulators, which has accelerated market expansion and growth.
  
• Additionally, increased funding for developing innovative therapies in the region is expected to boost the market further. For instance, the NIH reports that in 2023, the U.S. invested approximately USD 37.8 billion in medical research, with a large proportion dedicated to developing new therapies such as immunomodulators.
  
• These factors are likely to contribute to regional growth within the forecast period.
  

The immunomodulators market in UK is expected to experience significant and promising growth from 2024 to 2032.

• The demand for immunomodulators such as biologics and biosimilars in treatment protocols for rheumatoid arthritis and multiple sclerosis is increasing, driving market growth. According to NHS data, over 400,000 patients currently living in the UK have rheumatoid arthritis, and biologics adoption is helping improve treatment outcomes.
  
• Additionally, the surge in autoimmune conditions such as Crohn's disease and Lupus in the UK is driving the need for these therapies that effectively manage chronic conditions.
  
• The British Society of Gastroenterology states that about 115,000 persons in the UK are suffering from Crohn's disease, emphasizing the need for improved therapeutic methods.
  

Japan immunomodulators market is anticipated to witness lucrative growth between 2024 – 2032.

• Japan is witnessing a rapidly increasing elderly population, driving age-associated diseases such as cancers and autoimmune conditions and the immunomodulatory therapies used. The World Bank reports that as of 2023, Japan had 30% of their population aged 65 and older, the highest in the world.
  
• Moreover, the supportive regulatory environment will facilitate faster adoption of advanced immunomodulators, as the Japanese government is funding expedited approval processes for novel biologics and immunotherapies.
  

The immunomodulators market in South Africa is expected to experience significant and promising growth from 2024 to 2032.

• In an effort to improve the healthcare system and infrastructure in urban and rural areas, the government is proactively ensuring immunomodulatory drugs are adequately dispensed and utilized across the country.
  
• According to the World Health Organization, as of March 2021, nearly 84% of South Africa's population could access basic healthcare services, showing improvement from previous years.
  
• Moreover, South Africa has one of the highest HIV/AIDS prevalence rates globally. There is a growing dependence on immunomodulators such as immunostimulants to treat opportunistic infections and enhance the immune system of the severely immunocompromised population.
  
• In 2023, the Joint United Nations Program on HIV/AIDS reported that an estimated 7.8 million people were living with HIV in South Africa, highlighting the significant need for immunomodulatory treatments.
  

Immunomodulators Market Share

The market is very competitive as leading companies as well as smaller to medium-sized businesses aim to increase market share and expanding their global presence. A key market strategy is constant introduction of innovations such as chimeric antigen receptor T-cell therapy, JAK inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators. Major industry participants tend to encourage new developments through intense R&D spending, allowing them to gain additional industry control from their competitors. In order to strengthen their market position, major participants invest in strategic alliances, acquisitions, and even mergers, which is quite useful in the current shifting regulatory landscape.

Immunomodulators Market Companies

Some of the eminent market participants operating in the immunomodulators industry include:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited
• UCB S.A.
  
• Abbvie concentrates its efforts on the creation of novel immunomodulatory therapies that are skilfully developed with demonstrated effectiveness for chronic autoimmune diseases.
  
• Amgen produces biological and small-molecule immunomodulators which target certain pathways with the intention of improving clinical outcomes
  .
• Bristol-Myers Squibb deals with novel immunotherapy approaches, increasing immune modulations for cancer and autoimmune diseases.
  

Immunomodulators Industry News: 

• In March 2023, Pfizer Inc. announced the acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for a total enterprise value of USD 43 billion. This acquisition positioned Pfizer Inc. to enhance its oncology portfolio and accelerate the development of innovative cancer therapies, thereby strengthening its leadership in the oncology market
  
• In July 2021, Sanofi and Asahi Kasei Pharma Corporation announced the execution of a licensing agreement for the marketing of Plaquenil Tablets 200 mg for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) in Japan. This partnership enhanced Sanofi's market presence in Japan and facilitated greater access to effective treatments for patients suffering from these autoimmune conditions.
  

The immunomodulators market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Immunosuppressants
• Immunostimulants

Market, By Application

• Oncology
• Autoimmune diseases
• Infectious diseases
• Other applications

Market, By Distribution channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa